Trial Profile

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Trastuzumab-deruxtecan (Primary) ; ZN A 1041 (Primary)
Indications Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Solid tumours
Focus Adverse reactions
Sponsors Suzhou Zanrong Pharmaceutical Technology

30 Aug 2024 Planned End Date changed from 30 Oct 2024 to 30 Oct 2026.
30 Aug 2024 Planned primary completion date changed from 30 Oct 2023 to 30 Oct 2025.
26 Jul 2023 Planned End Date changed from 30 Nov 2023 to 30 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com